
Small Molecules
A Drug Designed to Mimic the Body's Own Rhythm Moves Into Phase 3
Linafexor is built to activate — then disappear. Early data suggest that timing, not just potency, may be what finally makes FXR agonism work.

Linafexor is built to activate — then disappear. Early data suggest that timing, not just potency, may be what finally makes FXR agonism work.
Peptide drugs don't usually survive stomach acid or cross the intestinal wall. Isthmus Biosciences says a transient permeation enhancer, not a new peptide, is what finally made an oral GLP-1 agonist work in Phase 2.
ALD-9102 was never screened from a physical library — it was sampled from a diffusion model trained on covalent fragment geometries. Eleven weeks later, it had a crystal structure. Fourteen months later, it had a Phase 1 trial.